TCM
TGTX icon

Tekla Capital Management’s TG Therapeutics TGTX Stock Holding History

Tekla Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-133,269
Closed -$6.93M – 213
2020
Q4 		$6.93M Buy
+133,269
New +$4.5M 0.24% 103

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Tekla Capital Management's TGTX Position: Q1 2021 in Review

Tekla Capital Management sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 133,269 shares — an estimated $6.93M sold.

Tekla Capital Management first reported a position in TGTX in Q4 2020 and held it in 1 quarter. The position peaked at $6.93M in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

  • Tekla Capital Management reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tekla Capital Management sold 133,269 TG Therapeutics shares in Q1 2021, an estimated $6.93M.
  • Tekla Capital Management first reported a position in TG Therapeutics in Q4 2020 and held it in 1 quarter.
  • Tekla Capital Management's TG Therapeutics position peaked at $6.93M in Q4 2020.
  • 240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.